Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses differences in ERβ signaling between rodents and humans and reports no new clinical results; the authors highlight the need for further research in humans before using ERβ agonists clinically.

In this animal study, finasteride exposure led to impaired spermatogenesis in rats, while the novel compound DA-9401, derived from three medicinal herbs, demonstrated potential in improving sperm parameters and reducing testicular apoptosis when used alone or with finasteride.

This review discusses the preclinical findings on cyproterone acetate and suggests that while it has a low potential cancer risk for patients, its tumor effects in female rats may involve both genotoxic and mitogenic mechanisms.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

This review discusses the potential role of androgen receptor CAG repeat polymorphism testing in hypogonadism management for both sexes, but its clinical utility remains unclear and requires further investigation.

In this study, the authors observed that testosterone therapy shortened the QTc interval and normalized T-wave morphology in men with acquired LQTS or TdP linked to hypogonadism, suggesting testosterone may be helpful in treatment.

This study identified 8-hydroxy germacrene B from Curcuma aeruginosa as a highly potent in-vitro 5-alpha reductase inhibitor with significant anti-androgenic activity, while exhibiting mild cytotoxicity on prostate cancer cells without affecting human dermal papilla cells at tested concentrations.

This case report found that a dog's progressive alopecia and prostatitis were caused by ingesting a transdermal estradiol cream, emphasizing the need to identify exogenous estrogen sources during evaluation.

This analysis of the Prostate Cancer Prevention Trial found that finasteride reduces prostate cancer risk by nearly 25% and enhances the PSA test's ability to detect prostate cancer and high-risk diseases.

This study found that Ganoderma lucidum extracts showed weak 5alpha-reductase inhibition but significantly inhibited prostate cell proliferation and testosterone-driven prostate growth in rats, suggesting potential as an ingredient for treating androgen-induced diseases.

This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.

This meta-analysis suggests that individuals with vertex baldness may have a higher risk of prostate cancer, though overall baldness is not significantly associated with prostate cancer risk.

This study identified potent dual inhibitors of 5α-reductases 1 and 2 that may aid in designing new drugs for related diseases.

This review discusses plant-derived phytochemicals, such as phytosterols, polyphenols, and fatty acids, as potential alternatives to 5-alpha-reductase inhibitors for prostate cancer treatment, highlighting their promising anti-cancer properties and potentially fewer side effects compared to conventional drugs.

In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.

This study reports that structural and biochemical analysis of steroid 5α-reductases clarifies how they mediate steroid reduction with NADPH, potentially aiding in designing targeted therapies.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

This study found that overexpression of the enzyme SSAT in a mouse model significantly reduced prostate tumor size and progression, suggesting it could be a promising strategy against prostate cancer.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

This study conducted a meta-analysis and found that men with both frontal and vertex male pattern baldness have a slightly increased risk of developing prostate cancer, though most data was from Caucasian populations and effect modification by genetic variations was not assessed.

This study observed that circulating testosterone affects baseline sex differences in voiding function in C57BL/6J mice, with prostate lobe mass having a lesser impact.

This study suggests that the adrenal gland may contribute to prostate cancer treatment resistance and indicates potential steroid production or dependency in ovarian cancer.

This study identifies SOX9 as a critical downstream effector of ERG in TMPRSS2:ERG fusion-positive prostate cancer, indicating its role in tumor invasion and growth.

Using finasteride with TIP extends time off period for prostate cancer patients.

In this study, dutasteride more effectively reduced prostate cancer cell viability than finasteride in vitro, but did not significantly alter the angiogenic response.

This study concluded that incorporating the percentage of free PSA and urinary markers improves the accuracy of determining the need for prostate biopsy.

This study suggests that dutasteride may be more beneficial than finasteride for therapeutic or preventive use.

This study found that finasteride reduced prostate cancer incidence by 30%, with no significant difference in Gleason scores compared to placebo after re-evaluation of pathology and extended follow-up.